Target intelligence / Profile preview

Signal sequence receptor subunit 1 pseudogene 2 (SSR1P2)

Target
SSR1P2
Molecular classification
Pseudogene, Non-coding RNA locus (by genomic annotation), Homolog to receptor subunit
01

Overview

Signal sequence receptor subunit 1 pseudogene 2 (SSR1P2) is a genomic locus classified as a *pseudogene* based on its high sequence homology to the functional SSR1 gene (which encodes a subunit of the signal sequence receptor complex on the endoplasmic reticulum)[2][3]. SSR1P2 contains mutations or sequence disablements—such as premature stop codons or frameshifts—that prevent the production of a functional protein product[3]. Like other processed pseudogenes, SSR1P2 may occasionally produce noncoding RNAs, but there is no evidence it encodes a receptor or any functional protein[2][3]. Pseudogenes can sometimes have subtle biological activity at the RNA level, such as influencing expression of related genes or acting as regulatory RNAs, but there are no published data supporting such a role for SSR1P2 specifically[2][1]. SSR1P2 is *not considered a receptor, enzyme, transporter, or any typical drug target*. In genome annotation databases, pseudogenes may pose challenges, as their sequences can confound molecular assays or be misannotated as functional genes[3].

Other names
Signal sequence receptor, alpha pseudogene 2SSR1P2
02

Mechanism of action

Not applicable; pseudogenes generally do not encode proteins or enzyme activities that can be targeted by drugs[3].

03

Biological functions

No direct protein-coding function[3]Pseudogenes like SSR1P2 can have regulatory roles at the RNA level, including acting as competing endogenous RNAs, microRNA decoys, or influencing parent gene expression[1][3]. However, specific roles for SSR1P2 are not described in published literature.
04

Disease associations

No direct disease role is assigned to SSR1P2[2][3].Generally, pseudogenes have been implicated in cancer and other diseases when they regulate oncogenes or tumor suppressors at the RNA level[1]. No such role is documented for SSR1P2 specifically.
05

Safety considerations

None documented; as a noncoding pseudogene, SSR1P2 does not directly pose therapeutic safety issues[3].
06

Biomarkers

None specific to SSR1P2; pseudogenes with regulatory RNA activity are sometimes investigated as biomarkers in research settings, but SSR1P2 is not [2][1].

Beyond the preview

Go deeper on Signal sequence receptor subunit 1 pseudogene 2 (SSR1P2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Signal sequence receptor subunit 1 pseudogene 2 (SSR1P2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call